166 related articles for article (PubMed ID: 28452226)
21. Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis.
Kin KC; Hill D; Feldman SR
Expert Rev Clin Pharmacol; 2016 Jun; 9(6):789-97. PubMed ID: 27089906
[TBL] [Abstract][Full Text] [Related]
22. Pharmacoeconomic evaluation of calcipotriol (Daivonex/Dovonex) and UVB phototherapy in the treatment of psoriasis: a Markov model for The Netherlands.
de Rie MA; de Hoop D; Jönsson L; Bakkers EJ; Sørensen M
Dermatology; 2001; 202(1):38-43. PubMed ID: 11244227
[TBL] [Abstract][Full Text] [Related]
23. A two-compound product containing calcipotriol and betamethasone dipropionate provides rapid, effective treatment of psoriasis vulgaris regardless of baseline disease severity.
van de Kerkhof PC; Wasel N; Kragballe K; Cambazard F; Murray S
Dermatology; 2005; 210(4):294-9. PubMed ID: 15942215
[TBL] [Abstract][Full Text] [Related]
24. Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris.
van de Kerkhof P; de Peuter R; Ryttov J; Jansen JP
Curr Med Res Opin; 2011 Jan; 27(1):225-38. PubMed ID: 21142833
[TBL] [Abstract][Full Text] [Related]
25. Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study.
Vena GA; Galluccio A; Pezza M; Vestita M; Cassano N
J Dermatolog Treat; 2012 Aug; 23(4):255-60. PubMed ID: 21756153
[TBL] [Abstract][Full Text] [Related]
26. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris.
Kragballe K; Austad J; Barnes L; Bibby A; de la Brassinne M; Cambazard F; Fleming C; Heikkilä H; Williams Z; Peyri Rey J; Svensson A; Toole J; Wozel G
Dermatology; 2006; 213(4):319-26. PubMed ID: 17135738
[TBL] [Abstract][Full Text] [Related]
27. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial.
Langley RG; Gupta A; Papp K; Wexler D; Østerdal ML; Curčić D
Dermatology; 2011; 222(2):148-56. PubMed ID: 21293107
[TBL] [Abstract][Full Text] [Related]
28. Treatment of nail psoriasis with a two-compound formulation of calcipotriol plus betamethasone dipropionate ointment.
Rigopoulos D; Gregoriou S; Daniel Iii CR; Belyayeva H; Larios G; Verra P; Stamou C; Kontochristopoulos G; Avgerinou G; Katsambas A
Dermatology; 2009; 218(4):338-41. PubMed ID: 19212110
[TBL] [Abstract][Full Text] [Related]
29. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris.
Kragballe K; Austad J; Barnes L; Bibby A; de la Brassinne M; Cambazard F; Fleming C; Heikkilä H; Jolliffe D; Peyri J; Svensson A; Toole J; Wozel G
Br J Dermatol; 2006 Jun; 154(6):1155-60. PubMed ID: 16704648
[TBL] [Abstract][Full Text] [Related]
30. Calcipotriol and betamethasone dipropionate (Dovobet, Daivobet): a new formulation for the treatment of psoriasis.
Poulin Y
Skin Therapy Lett; 2002 Jun; 7(6):1-3. PubMed ID: 12223976
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study.
Reich K; Zschocke I; Bachelez H; de Jong EM; Gisondi P; Puig L; Warren RB; Mrowietz U;
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1156-63. PubMed ID: 25346093
[TBL] [Abstract][Full Text] [Related]
32. Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp.
Kragballe K; van de Kerkhof P
J Eur Acad Dermatol Venereol; 2014 May; 28 Suppl 2():10-21. PubMed ID: 24684739
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and local safety of a calcipotriol/ betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris.
Parslew R; Traulsen J
Eur J Dermatol; 2005; 15(1):37-9. PubMed ID: 15701591
[TBL] [Abstract][Full Text] [Related]
34. Use of a psoriasis plaque test in the development of a gel formulation of calcipotriol and betamethasone dipropionate for scalp psoriasis.
Queille-Roussel C; Hoffmann V; Enevold A; Ganslandt C
J Dermatolog Treat; 2013 Aug; 24(4):250-4. PubMed ID: 22103604
[TBL] [Abstract][Full Text] [Related]
35. Once daily application of a combination of calcipotriol and betamethasone dipropionate (Dovobet, Daivobet) for the treatment of psoriasis.
Lui H; Shapiro J
Skin Therapy Lett; 2003; 8(Suppl 1):1-2. PubMed ID: 14961173
[TBL] [Abstract][Full Text] [Related]
36. Treatments for scalp psoriasis with emphasis on calcipotriol plus betamethasone dipropionate gel (Xamiol).
Guenther LC
Skin Therapy Lett; 2009 May; 14(4):1-4. PubMed ID: 19585059
[TBL] [Abstract][Full Text] [Related]
37. Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs.
Asche CV; Kim M; Feldman SR; Zografos P; Lu M
J Med Econ; 2017 Sep; 20(9):1000-1006. PubMed ID: 28581873
[TBL] [Abstract][Full Text] [Related]
38. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial.
Saraceno R; Andreassi L; Ayala F; Bongiorno MR; Giannetti A; Lisi P; Martini P; Peris K; Peserico A; Chimenti S
J Dermatolog Treat; 2007; 18(6):361-5. PubMed ID: 17934937
[TBL] [Abstract][Full Text] [Related]
39. Optimal maintenance treatment with calcipotriol/betamethasone dipropionate gel in Korean patients with psoriasis vulgaris: a multicentre randomized, controlled clinical trial.
Lee JH; Park CJ; Kim TY; Choe YB; Kim NI; Song HJ; Youn JI; Youn SW; Choi JH; Kim KJ
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):483-489. PubMed ID: 27723134
[TBL] [Abstract][Full Text] [Related]
40. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
Kircik LH
J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
